Association between the ACE-I/D polymorphism and nicotine dependence amongst patients with lung cancer

Abstract

The biologically active peptide angiotensin II is cleaved from angiotensinogen by the renin and the angiotensin converting enzyme (ACE), an enzymatic cascade known as the renin angiotensin system (RAS). RAS may be important in the etiology of nicotine dependence by influencing dopaminergic signaling. In the present study, the association between an insertion/deletion (I/D) polymorphism of ACE and nicotine dependence amongst patients with lung cancer was assessed. To date, several studies have shown the relevance of this polymorphic variant in both nicotine depen¬dence and lung cancer. However, the present study is the first to address the potential role of the ACE I/D polymorphism in nicotine dependence among patients with lung cancer. Genotyping was performed in 305 patients with lung cancer (males/females, 214/91). Significantly more male smokers had the ACE I allele compared with male non smokers (44.9 vs. 20.0%; P<0.05). The risk of smoking was ~5 fold higher for males with the ACE I allele (ACE II homozygous and ACE ID heterozygous) vs. ACE DD homozygous (odds ratio, 5.47; 95% confidence interval, 1.4 21.9; P=0.016). The pack year smoking history in a subgroup of females with squamous cell carcinoma carrying the ACE I allele was significantly lower compared with ACE DD (37.1±14.1 vs. 57.0±29.1; F=4.5; P=0.046). The ACE I/D polymorphism accounted for 17.6% of the smoking severity in this patient group (β, 0.42; multiple R2 change, 0.176; P=0.046). These results suggest that the ACE I/D polymorphism contributes to the risk of nicotine dependence and smoking severity in lung cancer patients in a sex specific manner.